Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies

• Published in: European journal of medicinal chemistry Vol. 109; pp. 216 - 237
• Main Authors: Migliore, Marco, Habrant, Damien, Sasso, Oscar, Albani, Clara, Bertozzi, Sine Mandrup, Armirotti, Andrea, Piomelli, Daniele, Scarpelli, Rita
• Format: Journal Article
• Language: English
• Published: ISSY-LES-MOULINEAUX Elsevier Masson SAS 15.02.2016; Elsevier
• Subjects: Amidohydrolases - antagonists & inhibitors; Amidohydrolases - metabolism; Animals; Anti-Inflammatory Agents, Non-Steroidal - chemistry; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Chemistry, Medicinal; COX; Cyclooxygenase 1 - metabolism; Cyclooxygenase 2 - metabolism; Cyclooxygenase Inhibitors - chemistry; Cyclooxygenase Inhibitors - pharmacology; Drug Design; FAAH; Humans; Hybrid scaffold; Inflammation; Life Sciences & Biomedicine; Mice; Multitarget inhibitors; Pharmacology & Pharmacy; Science & Technology; Stereoisomerism; Structure-Activity Relationship; FAAH; Inflammation; COX; Structure-activity relationship; Hybrid scaffold; Multitarget inhibitors; SELECTIVE-INHIBITION; ENDOCANNABINOID OXYGENATION; CYCLOOXYGENASE-2; ANANDAMIDE; ENDOGENOUS CANNABINOID SYSTEM; ENZYME; PAIN; ACID AMIDE HYDROLASE; DUAL INHIBITORS; MODULATION
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2015.12.036

Non-steroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological effects by inhibiting cyclooxygenase (COX)-1 and COX-2. Though widely prescribed for pain and inflammation, these agents have limited utility in chronic diseases due to serious mechanism-based adverse events such as gastrointestinal damage. Concomitant blockade of fatty acid amide hydrolase (FAAH) enhances the therapeutic effects of the NSAIDs while attenuating their propensity to cause gastrointestinal injury. This favorable interaction is attributed to the accumulation of protective FAAH substrates, such as the endocannabinoid anandamide, and suggests that agents simultaneously targeting COX and FAAH might provide an innovative strategy to combat pain and inflammation with reduced side effects. Here, we describe the rational design and structure-active relationship (SAR) properties of the first class of potent multitarget FAAH-COX inhibitors. A focused SAR exploration around the prototype 10r (ARN2508) led to the identification of achiral (18b) as well as racemic (29a-c and 29e) analogs. Absolute configurational assignment and pharmacological evaluation of single enantiomers of 10r are also presented. (S)-(+)-10r is the first highly potent and selective chiral inhibitor of FAAH-COX with marked in vivo activity, and represents a promising lead to discover novel analgesics and anti-inflammatory drugs. [Display omitted] •Rational design - SAR exploration of the first class of potent multitarget inhibitors of FAAH and COX enzymes.•Focused SAR studies around 10r (ARN2508) identified novel leads 18b and 29a-c, e.•Stereochemical and pharmacological studies of 10r enantiomers are reported.•Animal studies indicate that (S)-(+)-10r strongly inhibits FAAH and COX activities in vivo.